Doc, thanks for your well thought out and detailed response.
Good luck with treating all your patients.
What do you think of A2-73 possibility getting early FDA approval during their upcoming Phase-3 Alzheimer trail while in late progress; considering first of all the safety indications of the drug, but most of all the dire need of suffers 'if' it shows excellent efficacy, and notable improvement or stabilization among a significant percentage of the trial patients?